IPO registrations (S-1, F-1) · Registrants
Clovis Oncology, Inc.
- SEC CIK
- 1466301 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2011-06-23, last 2012-03-30; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2011-11-16; declared effective 2011-11-15
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 5500 FLATIRON PARKWAY, SUITE 100, Boulder, CO 80301
- EIN
- 90-0475355
- EDGAR entity type
- operating
- Insiders and CEO pay
- Clovis Oncology, Inc. on the corporate pages
Offering terms
- Proposed price range
- $13.00–$15.00 per share (S-1/A filed 2011-10-31)
- Final price
- $13.00 per share, within the range (424B1 filed 2011-11-16, an initial public offering)
- Shares sold
- 10,000,000
- Gross proceeds
- $130,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CLVS
- Lead underwriters
- Credit Suisse (3,800,000 shares)
- Syndicate
- J.P. Morgan; Leerink Partners (1,500,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CLOVIS ONCOLOGY, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: CLOVIS ONCOLOGY, INC. EXACT (EIN (EXACT))
- Federal award recipient: CLOVIS ONCOLOGY, INC. Fuzzy (name and state)
- SEC filer: Clovis Oncology, Inc. EXACT (CIK (EXACT))
- Person page: Krishna Kittu Kolluri Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
- Person page: Richard A Fair Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-06-23 | S-1 | S-1 (registration) | Clovis Oncology, Inc. | 0000950123-11-061021 ↗ |
| 2011-08-05 | S-1/A | S-1/A (amendment) | Clovis Oncology, Inc. | 0000950123-11-073669 ↗ |
| 2011-08-31 | S-1/A | S-1/A (amendment) | Clovis Oncology, Inc. | 0000950123-11-081490 ↗ |
| 2011-10-31 | S-1/A | S-1/A (amendment) | Clovis Oncology, Inc. | 0000950123-11-093276 ↗ |
| 2011-11-15 | EFFECT | EFFECT (declared effective) | Clovis Oncology, Inc. | 9999999995-11-003302 ↗ |
| 2011-11-16 | 424B1 | 424B1 (final prospectus) | Clovis Oncology, Inc. | 0000950123-11-099171 ↗ |
| 2012-03-23 | S-1 | S-1 (registration) | Clovis Oncology, Inc. | 0001193125-12-128037 ↗ |
| 2012-03-30 | S-1/A | S-1/A (amendment) | Clovis Oncology, Inc. | 0001193125-12-143880 ↗ |
| 2012-04-03 | EFFECT | EFFECT (declared effective) | Clovis Oncology, Inc. | 9999999995-12-000931 ↗ |
| 2012-04-04 | 424B1 | 424B1 (final prospectus) | Clovis Oncology, Inc. | 0001193125-12-149698 ↗ |
| 2013-05-02 | EFFECT | EFFECT (declared effective) | Clovis Oncology, Inc. | 9999999995-13-001387 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2011-10-31 | S-1/A | registration statement | $13.00–$15.00 | 9,300,000 | - | Nasdaq CLVS | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2011-11-16 | 424B1 | final prospectus | $13.00 | 10,000,000 | $130,000,000 | Nasdaq CLVS | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Allen Andrew R | Officer | See General Remarks; See Remarks; SEE REMARKS | 10 | 2011–2015 | |
| ATWOOD BRIAN G | Director; Director,TenPercentOwner | 18 | 2011–2021 | ||
| BARRETT M JAMES | Director; Director,TenPercentOwner | 13 | 2011–2018 | ||
| BARRIS PETER J | TenPercentOwner | 3 | 2011–2013 | ||
| BASKETT FOREST | TenPercentOwner | 3 | 2011–2013 | ||
| BLAIR JAMES C | Director; Director,TenPercentOwner | 27 | 2011–2021 | ||
| DOMAIN ASSOCIATES | TenPercentOwner | 1 | 2011 | ||
| DOMAIN PARTERS VII L P | TenPercentOwner | 4 | 2011–2013 | ||
| DOVEY BRIAN H | TenPercentOwner | 6 | 2011–2013 | ||
| DP VII ASSOCIATES LP | TenPercentOwner | 4 | 2011–2013 | ||
| DRANT RYAN D | TenPercentOwner | 3 | 2011–2013 | ||
| Halak Brian K | TenPercentOwner | 6 | 2011–2013 | ||
| Hoerter Steven L. | Officer | See Remarks; SEE REMARKS | 10 | 2011–2015 | |
| IVERS-READ GILLIAN C | Officer | See Remarks; SEE REMARKS | 71 | 2011–2022 | |
| KERINS PATRICK J | TenPercentOwner | 3 | 2011–2013 | ||
| KOLLURI KRISHNA KITTU | TenPercentOwner | 3 | 2011–2013 | person page Fuzzy | |
| KRAMLICH C RICHARD | TenPercentOwner | 2 | 2011 | ||
| MAHAFFY PATRICK J | Director,Officer | President and CEO; See Remarks | 17 | 2011–2022 | |
| MAST ERLE T | Officer | Executive VP and CFO | 16 | 2011–2015 | |
| McKinley Edward J | Director | 17 | 2011–2021 | ||
| MOTT DAVID M | TenPercentOwner | 3 | 2011–2013 | ||
| NEA 13 GP, Ltd | TenPercentOwner | 3 | 2011–2013 | ||
| NEA Partners 13, Limited Partnership | TenPercentOwner | 3 | 2011–2013 | ||
| NEW ENTERPRISE ASSOCIATES 13 LP | TenPercentOwner | 3 | 2011–2013 | ||
| REED JOHN C | Director | 2 | 2011–2012 | ||
| SANDELL SCOTT D | TenPercentOwner | 3 | 2011–2013 | ||
| SCHOEMAKER KATHLEEN K | TenPercentOwner | 6 | 2011–2013 | ||
| SPICKSCHEN THORLEF | Director | 22 | 2011–2021 | ||
| TREU JESSE I | TenPercentOwner | 6 | 2011–2013 | ||
| Versant Side Fund IV, L.P. | TenPercentOwner | 3 | 2011–2013 | ||
| Versant Venture Capital IV, L.P. | TenPercentOwner | 3 | 2011–2013 | ||
| Versant Ventures IV, LLC | TenPercentOwner | 3 | 2011–2013 | ||
| Viswanathan Ravi | TenPercentOwner | 3 | 2011–2013 | ||
| VITULLO NICOLE | TenPercentOwner | 6 | 2011–2013 | ||
| Weller Harry R | TenPercentOwner | 3 | 2011–2013 | ||
| Kamdar Kim P. | TenPercentOwner | 1 | 2011 | ||
| KLINGENSTEIN PAUL H | Director | 13 | 2012–2021 | ||
| Flaherty Keith T. | Director | 10 | 2013–2021 | ||
| GRAHAM GINGER L | Director | 10 | 2013–2021 | ||
| Rolfe Lindsey | Officer | See remarks; See Remarks | 54 | 2015–2022 | |
| Hooks Corwin Dale | Officer | See remarks; See Remarks | 17 | 2016–2018 | |
| MUEHL DANIEL W | Officer | See remarks; See Remarks | 53 | 2016–2022 | |
| Azelby Robert | Director | 5 | 2018–2021 | ||
| Fair Richard A. | Director | 5 | 2018–2021 | person page Fuzzy | |
| Gross Paul Edward | Officer | See Remarks | 30 | 2019–2022 | |
| Harding Thomas C. | Officer | See Remarks | 27 | 2020–2022 | |
| Simantov Ronit | Director | 2 | 2021 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CLOVIS ONCOLOGY, INC. | CO | State business registries | name and state |
| Plan sponsor | CLOVIS ONCOLOGY, INC. | CO | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Federal award recipient | CLOVIS ONCOLOGY, INC. | CO | Federal spending (USAspending) | name and state |
| Paying company | Clovis Oncology, Inc. | CO | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Clovis Oncology, Inc. | CO | Patents (USPTO) | name and state |
| SEC filer | Clovis Oncology, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Clovis Oncology, Inc. | CO | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | CLOVIS ONCOLOGY, INC. | EIN (EXACT) | ||
| Person page | Krishna Kittu Kolluri | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) | |
| Person page | Richard A Fair | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CO first:
- ALLOS THERAPEUTICS INC CO
- ARRAY BIOPHARMA INC CO
- MYOGEN INC CO
- PHARMION CORP CO
- GLOBEIMMUNE INC CO
- Statera Biopharma, Inc. CO
- AYTU BIOPHARMA, INC CO
- Ampio Pharmaceuticals, Inc. CO
- MusclePharm Corp CO
- United Cannabis Corp CO
In other datasets, the same topic (Health) in CO:
- Nonprofit: 3 4 FIGHTING PARKINSONS (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health